The health system is keeping up with CMS mandates for price transparency, requirements that will only grow over time, senior Finance VP says.
Category: Health Insurance
There’s A New ‘Medicare-For-All’ Bill In The House. Why Does It Matter?
The progressive proposal adds details to the discussion of this controversial approach to overhauling the nation’s health system, and Democratic primary candidates will have to be prepared to get more specific.
Investing in consumerism and technology requires scale, wise allocation of investments
Health systems should be allocating more resources to technologies that further the mission of creating a consumer-centric industry.
Travel and wait times for healthcare are the worst among professional sectors, Altarum report says.
When travel and wait times were quantified using hourly wage to measure "economic cost of time spent" the costs averaged $89 billion dollars annually, the analysis said.
Cancer’s Complications: Confusing Bills, Maddening Errors And Endless Phone Calls
Carol Marley has pancreatic cancer — and dealing with its financial toll has become her full-time job.
Senate Finance Committee wants pharma commitment for lower list prices on drugs
End rebates for both Medicare and commercial plans, and they will lower list prices, pharmaceutical executives say.
How healthcare mergers and acquisitions may actually harm patient satisfaction
Clinical quality itself doesn’t seem to suffer much, but patient perceptions can take a hit from market consolidation.
ACA’s pre-existing condition and age clauses had immediate impact on people with diabetes
The rise from 2014 to 2016 in the percentage of people with private health insurance coverage who had diabetes was sharpest among people in their 50s.
UConn Health, UW Medicine reveal major cyber incidents affecting more than 1 million patients
UConn Health incidents stemmed from illegal access to employee email accounts; UW Medicine detected a vulnerability on a website server that exposed protected internal files.
Seven big pharma executives are being asked to explain drug prices before Senate Finance Committee
On Tuesday morning, executives from seven pharmaceutical companies will face …
